Biopolymeric films as delivery vehicles for controlled release of hydrocortisone: Promising devices to treat chronic skin diseases.

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease with nasty effects on the psychosocial wellbeing of patients. Overall, glucocorticoids, such as hydrocortisone (HC), are the primary pharmacologic drugs used to treat AD and its symptoms. However, the long-term treatment with HC is often accompanied by severe adverse effects. So, this study reports the encapsulation of HC in polymeric films based on gelatin (Gel) and gelatin/starch (Gel/St) and investigates their potential to treat and attenuate 2,4-Dinitrochlorobenzene (DNCB)-induced AD-like symptoms in BALB/c mice model. The prepared films were characterized by different techniques, which indicated that HC was physically entrapped into the polymer matrices. In vitro experiments indicate that the HC release process occurs in a controlled manner (up to 48 h) for both films. Regarding the in vivo experiments, HC-loaded films (Gel@HC and Gel/St@HC), unloaded films (Gel and Gel/St) and HC cream (1%) (as reference) were applied topically on the back of the DNCB-sensitized animals and skin severity scores and scratching behavior were determined. Ex-vivo experiments were done to quantify inflammatory and/or biochemical parameters. As assessed, the topical application of the biopolymeric films (loaded or not with HC) improved the inflammatory parameters, while a lower corticosterone level was observed for the animals treated with Gel and Gel@HC films. In summary, the HC-loaded films showed superior efficiency to treat/attenuate the analyzed parameter than the HC cream (1%). Further, no death or sign of toxicity was observed in animals exposed to HC-loaded films. Thus, the encapsulation of HC in biopolymeric films seems to be a promising alternative for the treatment of injuries caused by chronic skin diseases that require prolonged use of glucocorticoids.